NASDAQHealth CareHealth Information ServicesSnapshot 2026-07-23
Reading HCAT? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a turnaround story focused on strategic transformation, particularly in AI-driven technology. The current thesis state is mixed, with management's execution being volatile and recent financial performance showing weakness.
The market appears to price in a durable premium compared to peers, indicating that expectations are somewhat elevated. There is a notable expectations gap, suggesting that investors may be anticipating better performance than what has been delivered recently.
Fundamentals are likely to remain under pressure in the near term, as the company is currently loss-making and has experienced declining revenue. Management's focus on improving cash from operations and restructuring efforts may take time to yield positive results.
The future performance of HCAT hinges on management's ability to execute its strategic transformation and the overall health of the Healthcare sector. Key swing factors include the performance of sector bellwethers like VEEV, BTSG, and TEM, which could influence market sentiment and HCAT's trajectory.
In the next 1 to 3 years, HCAT's path will depend on its execution of strategic initiatives and external sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Improving cash flow is key for Health Catalyst to support its operations and growth.
Confirms:Cash from operations shows a year-over-year increase of at least 10%.
Disproves:Cash from operations goes down or stays the same each year.
Why it matters: Earnings results will show how well the company is doing. They also show changes.
Confirms one read:Earnings are better than market expectations. This shows strong performance.
Confirms the other:Earnings are below expectations. This raises worries about financial health.
Why it matters: Improving cash flow shows better financial health. It can help offset operating losses.
Confirms:Q2 cash from operations is over $18.5M. This shows ongoing improvement.
Disproves:Q2 cash from operations falls below $18.5M, indicating cash flow issues.
Why it matters: Hitting or beating revenue goals shows progress for Health Catalyst's changes.
Confirms:Total revenue for Q2 2026 reported between $68 million and $70 million.
Disproves:Total revenue is below $68 million. This shows ongoing problems for the business.
Why it matters: Project Nexus aims to transform operations. Success or failure will impact future performance.
Confirms one read:Management says Project Nexus is doing well. They report strong operational metrics.
Confirms the other:Management reports problems with Project Nexus. This leads to more job cuts.
Why it matters: Losing more money can mean bigger problems. This can hurt long-term success.
Confirms:Q2 operating income loss is over $106.5M. This shows worsening financial health.
Disproves:Q2 operating income loss is under $106.5M. This shows better management.
Why it matters: The health care sector's growth trends can affect Health Catalyst's performance and outlook.
Confirms one read:Revenue growth in the health care sector re-accelerates back toward 10% or higher.
Confirms the other:Sector revenue growth slows down to below 5%.
Why it matters: The sale could affect Health Catalyst's finances and focus.
Confirms one read:Finishing the sale brings positive cash flow or a strategic edge.
Confirms the other:The sale does not close or results in a negative financial impact.
Why it matters: How well the job cuts work will be key for Health Catalyst's model.
Confirms:Operating losses drop a lot in the next quarterly report.
Disproves:Operating losses stay high or get worse. This shows cost cuts are not working.
Why it matters: Closing this deal will confirm Health Catalyst's focus on core AI technology and improve its balance sheet.
Confirms:The divestiture will close by the end of 2026. It will meet all rules.
Disproves:The divestiture does not close. This is due to unmet rules or other problems.
